167 related articles for article (PubMed ID: 31428578)
1. First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma-A Retrospective Study.
Viscuse PV; Price KA; Garcia JJ; Schembri-Wismayer DJ; Chintakuntlawar AV
Front Oncol; 2019; 9():701. PubMed ID: 31428578
[No Abstract] [Full Text] [Related]
2. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.
van Boxtel W; Locati LD; van Engen-van Grunsven ACH; Bergamini C; Jonker MA; Fiets E; Cavalieri S; Tooten S; Bos E; Quattrone P; Verhaegh GW; Schalken JA; Licitra L; van Herpen CML;
Eur J Cancer; 2019 Mar; 110():62-70. PubMed ID: 30771738
[TBL] [Abstract][Full Text] [Related]
3. Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.
Kawakita D; Nagao T; Takahashi H; Kano S; Honma Y; Hirai H; Saigusa N; Akazawa K; Tani K; Ojiri H; Tsukahara K; Ozawa H; Okami K; Kondo T; Togashi T; Fushimi C; Shimura T; Shimizu A; Okamoto I; Okada T; Imanishi Y; Watanabe Y; Otsuka K; Sakai A; Ebisumoto K; Sato Y; Yamazaki K; Ueki Y; Hanazawa T; Saito Y; Ando M; Matsuki T; Nakaguro M; Sato Y; Urano M; Utsumi Y; Kohsaka S; Saotome T; Tada Y
Ther Adv Med Oncol; 2022; 14():17588359221119538. PubMed ID: 36090801
[TBL] [Abstract][Full Text] [Related]
4. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
van Boxtel W; Verhaegh GW; van Engen-van Grunsven IA; van Strijp D; Kroeze LI; Ligtenberg MJ; van Zon HB; Hendriksen Y; Keizer D; van de Stolpe A; Schalken JA; van Herpen CM
Int J Cancer; 2020 Jun; 146(11):3196-3206. PubMed ID: 31745978
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.
Boon E; van Boxtel W; Buter J; Baatenburg de Jong RJ; van Es RJJ; Bel M; Fiets E; Oosting SF; Slingerland M; Hoeben A; Tesselaar MET; Jonker MA; Flucke UE; ; van der Graaf WTA; van Herpen CML
Head Neck; 2018 Mar; 40(3):605-613. PubMed ID: 29272069
[TBL] [Abstract][Full Text] [Related]
6. A Pitfall of the Androgen Deprivation Therapy for Salivary Duct Carcinoma: Hormonal Therapy-Induced Castrate-Resistant Prostate Cancer.
Yajima S; Nakanishi Y; Matsumoto S; Tanabe K; Masuda H
J Maxillofac Oral Surg; 2022 Dec; 21(4):1097-1100. PubMed ID: 36896090
[TBL] [Abstract][Full Text] [Related]
7. Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature.
You Y; Wang P; Wan X; Xu L; Gong Y; Zhang W
Onco Targets Ther; 2021; 14():3481-3486. PubMed ID: 34093024
[TBL] [Abstract][Full Text] [Related]
8. Combined androgen deprivation therapy in recurrent androgen-receptor-positive salivary duct carcinoma - a case report and review of the literature.
Poxleitner P; Shoumariyeh K; Steybe D; Hupfer V; Voss PJ; Rawluk J; Ermer M; Miething C; Schmelzeisen R; Duyster J
J Stomatol Oral Maxillofac Surg; 2020 Nov; 121(5):599-603. PubMed ID: 31904529
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N
Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
[TBL] [Abstract][Full Text] [Related]
10. Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy.
Soper MS; Iganej S; Thompson LD
Head Neck; 2014 Jan; 36(1):E4-7. PubMed ID: 23720164
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified.
Sousa LG; Wang K; Torman D; Binks BJ; Rubin ML; Andersen CR; Lewis WE; Rivera MJ; Kaya D; El-Naggar AK; Hanna EY; Esmaeli B; Frank SJ; Bell D; Glisson BS; Rodon J; Meric-Bernstam F; Lee JJ; Ferrarotto R
Cancer; 2022 Feb; 128(3):509-518. PubMed ID: 34661906
[TBL] [Abstract][Full Text] [Related]
12. The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers.
Hanna GJ; Bae JE; Lorch JH; Haddad RI; Jo VY; Schoenfeld JD; Margalit DN; Tishler RB; Goguen LA; Annino DJ; Chau NG
Oncologist; 2020 Jul; 25(7):598-608. PubMed ID: 32310325
[TBL] [Abstract][Full Text] [Related]
13. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
15. Androgen Receptor Signaling in Salivary Gland Cancer.
Dalin MG; Watson PA; Ho AL; Morris LG
Cancers (Basel); 2017 Feb; 9(2):. PubMed ID: 28208703
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer.
Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M
Int J Clin Oncol; 2016 Feb; 21(1):148-55. PubMed ID: 26141133
[TBL] [Abstract][Full Text] [Related]
17. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
18. Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation.
Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
Int J Clin Oncol; 2019 Oct; 24(10):1247-1255. PubMed ID: 31152322
[TBL] [Abstract][Full Text] [Related]
19. HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients.
Cavalieri S; Nuzzolese I; Ottini A; Bergamini C; Resteghini C; Colombo E; Alfieri S; Quattrone P; Calareso G; Iacovelli NA; Franceschini M; Licitra L
Front Oncol; 2022; 12():1096068. PubMed ID: 36733354
[TBL] [Abstract][Full Text] [Related]
20. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.
Locati LD; Perrone F; Cortelazzi B; Lo Vullo S; Bossi P; Dagrada G; Quattrone P; Bergamini C; Potepan P; Civelli E; Fallai C; Pilotti S; Licitra L
Head Neck; 2016 May; 38(5):724-31. PubMed ID: 25522335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
